Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Phio Pharmaceuticals Corp. | d488401dex321.htm |
| EX-31.1 - EX-31.1 - Phio Pharmaceuticals Corp. | d488401dex311.htm |
| 10-K - FORM 10-K - Phio Pharmaceuticals Corp. | d488401d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
RXi Pharmaceuticals Corporation
Marlborough, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (Nos. 333-183633, 333-189521, 333-189522, 333-215870 and 333-215871) of RXi Pharmaceuticals Corporation of our report dated March 26, 2018, relating to the consolidated financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Boston, Massachusetts
March 26, 2018